Fundamentals of Health

I am excited to announce that my new online course, Fundamentals of Health, is available for registration.

As many of you are aware, I have meticulously documented dozens of natural therapies in online courses that reverse symptoms such as tremors and mobility challenges. My new course addresses a bigger issue:

What basic support does the body need to maintain a steady state of health as we age as well as reverse whatever symptoms we currently experience?

Hosting interviews with 300 guests on Parkinsons Recovery Radio has proven very beneficial for me personally. It has given me the unique opportunity to pick and choose therapies that research and users report have been most beneficial. These choices have paid off for me personally. I am 100% healthy today.

My new course demonstrates therapies I personally use to support the ability of my body to sustain excellent health. Research evidence that supports the efficacy of these therapies is also included.

Click on the link below to watch a video about my new course and register which involves a one time tuition payment of only $25.

Robert Rodgers, Ph.D.
robert@parkinsonsrecovery.com
Olympia, Washington
877-526-4646

 

Pulsed Electromagnetic Field Therapy: The BEMER

Below I have included abstracts of two recent studies that report PEMF (Pulsed Electromagnet Field) therapy offers relief for both movement disorders and tremors.

I have personally used the BEMER (the gold standard of PEMF therapies and the only FDA approved device) for several years now with marvelous results. With aging, tiny passage ways through which blood circulates – known as capillaries –  narrow and eventually shut down as circulation conduits. Seventy-five percent of the circulation throughout the body is delivered by the capillaries, not arteries or veins. The BEMER opens up circulation passageways throughout the body.

What are the benefits of this? First, essential nutrients are delivered to the cells.  Second, waste that accumulates in the cells is removed. In short, the body begins to function more effectively and efficiently.

For more information about the BEMER visit:
https://robert-rodgers.bemergroup.com/en_US/human-line/home

Below are listed abstracts of the two recent PEMF studies. This first reports on the benefits of PEMF for movement disorders. The second reports on benefits for tremors.

Movement Disorders

PLoS One. 2021 Apr 28;16(4):e0248800. Long-term treatment with transcranial pulsed electromagnetic fields improves movement speed and elevates cerebrospinal erythropoietin in Parkinson’s disease. Bente Rona Jensen, Anne Sofie Bøgh Malling, Sissel Ida Schmidt, Morten Meyer, Bo Mohr Morberg, Lene Wermuth

Abstract

Background: Parkinson’s disease is characterized by motor dysfunctions including bradykinesia. In a recent study, eight weeks of daily transcranial stimulation with bipolar pulsed electromagnetic fields improved functional rate of force development and decreased inter-hand tremor coherence in patients with mild Parkinson’s disease.

Objective: To investigate the effect of long-term treatment with transcranial bipolar pulsed electromagnetic fields on motor performance in terms of movement speed and on neurotrophic and angiogenic factors.

Methods: Patients diagnosed with idiopathic Parkinson’s disease had either daily 30-min treatment with bipolar (±50 V) transcranial pulsed electromagnetic stimulation (squared pulses, 3ms duration) for three eight-week periods separated by one-week pauses (T-PEMF group) (n = 16) or were included in a PD-control group (n = 8). Movement speed was assessed in a six-cycle sit-to-stand task performed on a force plate. Cerebrospinal fluid and venous blood were collected and analyzed for erythropoietin and vascular endothelial growth factor.

Results: Major significant improvement of movement speed compared to the natural development of the disease was found (p = 0.001). Thus, task completion time decreased gradually during the treatment period from 10.10s to 8.23s (p<0.001). The untreated PD-control group did not change (p = 0.458). The treated group did not differ statistically from that of a healthy age matched reference group at completion of treatment. Erythropoietin concentration in the cerebrospinal fluid also increased significantly in the treated group (p = 0.012).

Conclusion: Long-term treatment with transcranial bipolar pulsed electromagnetic fields increased movement speed markedly and elevated erythropoietin levels. We hypothesize that treatment with transcranial bipolar pulsed electromagnetic fields improved functional performance by increasing dopamine levels in the brain, possibly through erythropoietin induced neural repair and/or protection of dopaminergic neurons.

Tremors

Neurol Sci. 2023 Feb;44(2):461-470.Physical therapy interventions for the management of hand tremors in patients with Parkinson’s disease: a systematic review. Mostafa Shahien, Abdelrahman Elaraby, Mohamed Gamal, Eslam Abdelazim, Basel Abdelazeem, Hazem S Ghaith, Ahmed Negida

Abstract

Background: Several physical therapy modalities have been used to improve hand tremors in patients with Parkinson’s disease (PD). However, little is known about the efficacy of these techniques. Therefore, we conducted this study to synthesize evidence from published studies on the efficacy of physical therapy techniques for hand tremors in PD patients.

Methods: We followed the PRISMA statement and Cochrane handbook guidelines when conducting this study. We conducted an electronic literature search of PubMed, Cochrane Central Register of Clinical Trials, Web of Science, Ovid, and Embase, and then we selected clinical trials assessing the efficacy of any physical therapy intervention for hand tremors in patients with PD. Study outcomes were extracted, and evidence was synthesized narratively.

Results: A total of six modalities described in six studies were included in this systematic review. Out of the six interventions, the tremor’s glove and electrical stimulation showed significant improvements in root mean square angular velocity (59% and 43.8%, respectively) and UPDRS tremor score (P < 0.05 for both). Also, eccentric exercises were associated with significant reductions in the mean resting tremor amplitude (P < 0.05). These data were dependent on single studies; therefore, a meta-analysis was not feasible.

Conclusion: Several physical therapy interventions, such as electrical stimulation, exercises, transcranial low voltage pulsed electromagnetic fields, weights, and virtual reality showed promising results in reducing hand tremors. 

J Neuroeng Rehabil . 2019 Jan 31;16(1):19. The effect of 8 weeks of treatment with transcranial pulsed electromagnetic fields on hand tremor and inter-hand coherence in persons with Parkinson’s disease. Anne Sofie Bøgh Malling, Bo Mohr Morberg, Lene Wermuth, Ole Gredal, Per Bech, Bente Rona Jensen

Abstract

Background: Parkinson’s disease (PD) tremor comprises asymmetric rest and postural tremor with unilateral onset. Tremor intensity can be amplified by stress and reduced by attention, and the medical treatment is complex. Mirror movements and unintentional synchronization of bimanual movements, possibly caused by insufficient inhibition of inter-hemispheric crosstalk, have been reported in PD, indicating a lag of lateralization. Potential neuroprotective effects of pulsed electromagnetic fields (PEMF) have been reported in-vitro and in rodents, as have influences of PEMF on human tremor. The aim was to investigate the effect of 8 weeks daily transcranial PEMF treatment (T-PEMF) of persons with PD on rest and postural hand tremor characteristics and on inter-hand coherence.

Methods: Hand accelerations of 50 PD participants with uni- or bilateral tremor participating in a clinical trial were analysed. A rest and postural tremor task performed during serial subtraction was assessed before and after 8 weeks of T-PEMF (30 min/day, 50 Hz, ±50 V, 3 ms squared pulses) or placebo treatment (sham stimulation 30 min/day). Forty matched healthy persons (no treatment) were included as reference. Intensity and inter-hand coherence related measures were extracted.

Results: The T-PEMF treatment decreased the inter-hand coherence in the PD group with unilateral postural tremor. The PD group with unilateral postural tremor was less clinically affected by the disease than the PD group with bilateral postural tremor. However, no differences between T-PEMF and placebo treatment on either intensity related or coherence related measures were found when all persons with PD were included in the analyses. The peak power decreased and the tremor intensity tended to decrease in both treatment groups.

Conclusions: Eight weeks of T-PEMF treatment decreased inter-hand coherence in the PD group with unilateral postural tremor, while no effects of T-PEMF treatment were found for the entire PD group. The unilateral postural tremor group was less clinically affected than the bilateral postural tremor group, suggesting that early treatment initiation may be beneficial. In theory, a reduced inter-hand coherence could result from a neuronal treatment response increasing inter-hemispheric inhibition

Update from Chris Hageseth MD

Click on the Radio Show Page link below to hear my interview this week with retired Psychiatrist Chris Hageseth who provides us with an update on his journey down the road to recovery.
I have interviewed him three times previously.
  1. September 2016: Five years no medications. Parkinson’s improving. How I had gone for 5 years without meds and was doing well using exercise and yoga
  2. January 2017: Wholistic (or holistic) how different PWPs approach their treatment.
  3. October 2018: Shifting the Parkinson’s disease
    mindset.

This is Chris’ fourth appearance as a guest on the radio show.  He stills hold to his beliefs.  Below I have posted a summary he provided us of his experience to date. 

  1. EXERCISE. EXERCISE, EXERCISE. I cannot exercise as hard as I did before. Gradually I had to walk more and jog less. Could only 3 – 4 miles.
  2. More convinced than ever that MINDSET/ATTITUDE is the key, PARKINSON’S IS A CHALLENGE, NOT A CURSE.  When I was formally diagnosed, I was 70 years old. Life expectancy for me was 84.1. Well, now I’m 82.4. In a year and a half, I will have reached my life expectancy.
  3. YOGA remains critical.
  4. WAIT UNTIL you really must take Levodopa. Levodopa induced dyskinesia (LID) is a real deal and can be disabling. Google it on YouTube. 
  • Let’s look at my life since we last met, year by year.

2018 – I shot a video titled So High So Low for the “I HAD A DREAM PROJECT” where I hiked a three mile walk trail and climbed a thousand feet. 

Link: https://www.ihadadreamproject.com/i-had-a-dream-project-videos 

That year I also went to Uganda to demonstrate the practices I used to manage so long without meds. (Robert, this is quite a tale, plus I have pictures.)

  • 2019 – After directing the local Parkinson’s support group, I resigned so new blood could take over.

BUT: New symptoms emerged that I didn’t know about:

  1. Anomia: a language specific disturbance arising after brain damage whose main symptom is the inability of retrieving known words. But it’s not dementia!
  2. Pseudo Bulbar Affect Crying or laughing excessively upon feeling any deep feeling.
  3. Dysphagia: difficulty or discomfort in swallowing as a symptom of disease. It starts out with mucus as postnasal drip. Get to an OT!
  4. Oily, flakey skin
  5. Sleep disturbances. Fall into deep sleep in the middle of the day. And then don’t sleep well at night.
  6. Pain in bed at night. Interfered with sleep.
  • 2020 – It was a remarkable and horrific year. PANDEMIC!

No more yoga classes! No gym with weightlifting. Social interaction approached zero. 

  • 2021 – Then, a condition worse than Parkinson’s emerged: Major Depression.

March 2021 – Fell and shattered right knee – 16 days in hospital.

July 2021 – Fell and broke my right hip.

August – Severe depression, I became suicidal.

September – Chose to have a course of electro-convulsive therapy (ECT)

October- It worked, and my PD improved a lot.

The falls were due to the antidepressant I was taking may increase fall for people with Parkinsons.

LESSON: Make sure you MD goes through all meds in case a med might make falling more likely

My story with Depression

Family history is strong.

Parkinson’s did not cause my suicidal depression, genetics and environment did.  Antidepressant medication failed to work and led to my falls!

2022 – I returned to my new normal. And that’s where I am today. I just have more symptoms and feel weaker.

I followed up with PWPs who I have advised in the past.

It became clear to me: I want to coach people with PD. 

I HAVE A LOT TO OFFER!

Teach PWPs how to become a “Bad Ass with PD.” 

No more withdrawal and depression.

My PD website: www.makemostofpd.com  

Robert, I want to come back with a program I have just developed to make being a person with PD and their caregiver have a better relationship. 

New website www.the-kindness-dialogue.com 

Robert Rodgers PhD

Insulin Resistance

Insulin resistance correlated with Parkinson’s symptoms: One of the most ground breaking research discoveries of the past decade ….

Are you tired all the time. Do you usually have little energy?

The breakdown of glucose synthesis may well be the reason. Metabolically, insulin receptors play a key role in the regulation of glucose homeostasis, Insulin signaling controls access to blood glucose in body cells.

Do you typically feel better in the morning before you have had something to eat? This is a clue that you may be susceptible to insulin resistance. Fasting over night means that is a 12 hour or more period you have not eaten anything. This is the condition needed by the body for the liver to manufacture ketones. Before eating anything in the morning. your brain is being efficiently fueled by ketones rather than glucose which is the by product of eating anything.

Epidemiological evidence and experimental data support the interaction between Parkinson’s and diabetes. Treatments for diabetes show promising neuro-protective results in PD patients for both diabetic and non-diabetic patients, Therefore, the role of anti-diabetic treatments for Parkinson’s patients offers a promising therapeutic approach

Ask your self – why are so many persons diagnosed with neurological conditions so thin? A logical reason is that when they eat, their symptoms worsen, so they do not eat regularly

Studies that find the connection between insulin resistance and Parkinson’s symptoms

Mov Disord. 2022 Aug;37(8):1612-1623. The Impact of Type 2 Diabetes in Parkinson’s Disease. Dilan Athauda, James Evans, Anna Wernick, Gurvir Virdi, Minee L Choi, Michael Lawton, Nirosen Vijiaratnam, Christine Girges, Yoav Ben-Shlomo, Khalida Ismail, Huw Morris, Donald Grosset, Thomas Foltynie, Sonia Gandhi 

Abstract

Background: Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson’s disease (PD), but its effect on disease progression is not well understood.

Objective: The aim of this study was to investigate the influence of T2DM on aspects of disease progression in PD.

Methods: We analyzed data from the Tracking Parkinson’s study to examine the effects of comorbid T2DM on PD progression and quality of life by comparing symptom severity scores assessing a range of motor and nonmotor symptoms.

Results: We identified 167 (8.7%) patients with PD and T2DM (PD + T2DM) and 1763 (91.3%) patients with PD without T2DM (PD). After controlling for confounders, patients with Type 2 Diabetes had more severe motor symptoms, as assessed by Movement Disorder Society Unified Parkinson’s Disease Rating Scale, Part III (25.8 [0.9] vs. 22.5 [0.3] P = 0.002), and nonmotor symptoms, as assessed by Non-Motor Symptoms Scale total (38.4 [2.5] vs. 31.8 [0.7] P < 0.001), and were significantly more likely to report loss of independence (odds ratio, 2.08; 95% confidence interval [CI]: 1.34-3.25; P = 0.001) and depression (odds ratio, 1.62; CI: 1.10-2.39; P = 0.015). Furthermore, over time, patients with T2DM had significantly faster motor symptom progression (P = 0.012), developed worse mood symptoms (P = 0.041), and were more likely to develop substantial gait impairment (hazard ratio, 1.55; CI: 1.07-2.23; P = 0.020) and mild cognitive impairment (hazard ratio, 1.7; CI: 1.24-2.51; P = 0.002) compared with the PD group. 

Conclusions: In the largest study to date, T2DM is associated with faster disease progression in Parkinson’s, highlighting an interaction between these two diseases. Because it is a potentially modifiable metabolic state, with multiple peripheral and central targets for intervention, it may represent a target for alleviating parkinsonian symptoms and slowing progression to disability and dementia. 

Mov Disord. 2021 Jun;36(6):1420-1429. Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression. Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce 

Abstract

Background: Type 2 diabetes (T2DM) and Parkinson’s disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. 

Objective: The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data.

Methods: A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies.

Results: In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression.

Conclusions: Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression.   

J Parkinsons Dis. 2020;10(3):775-789. The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease. Julia L Y Cheong, Eduardo de Pablo-Fernandez, Thomas Foltynie Alastair J Noyce

Abstract

In recent years, an emerging body of evidence has forged links between Parkinson’s disease (PD) and type 2 diabetes mellitus (T2DM). In observational studies, those with T2DM appear to be at increased risk of developing PD, as well as experiencing faster progression and a more severe phenotype of PD, with the effects being potentially mediated by several common cellular pathways. The insulin signalling pathway, for example, may be responsible for neurodegeneration via insulin dysregulation, aggregation of amyloids, neuroinflammation, mitochondrial dysfunction and altered synaptic plasticity. In light of these potential shared disease mechanisms, clinical trials are now investigating the use of established diabetes drugs targeting insulin resistance in the management of PD.  

Robert

The Truth About Hydration

Everyone knows that without water we die. We also all know that a dehydrated body has no chance of clearing toxins or sustaining life.
How many of us realize we are dehydrated? I seem never to realize I need to drink water. I have heard from many members of my audience who report that they drink a lot of water so they could certainly not be dehydrated.
But guess what? Dehydration may be a primary reason for their symptoms.

Take a few minutes today to hear my interview with Jaroslav Boublik, an international expert on dehydration. His answers to my questions will likely surprise you.
Robert

What Distinguishes People Who Celebrate Successful Recoveries from Those Who Do Not

I personally find the argument Stephen Fowkes puts forth in this clip of my interview with him compelling. Many persons I have interviewed over the years are literally stuck “in the mud”, attempting to decide which therapies offer the promise of relief but unable to decide which one to pursue. One option after another are offered, but none seem plausible enough to act on.

Does this by any chance describe you? It does most people. The one criticism of Parkinsons Recovery has been that people become overwhelmed by the many viable choices are tendered that offer the promise of symptom relief. There are too many choices to filter through, so no action is taken.

Stephen makes a compelling argument that the people who have successful recoveries are those that take action on something. He even goes so far as to say it does not really matter what options are embraced. The secret to recovery is to take full control over your recovery program. So Stephen simply recommends that you act, do not hesitate. Take the steps your intuition informs are right for you in the moment. In doing so, you will celebrate symptom relief down the line and lead a full, productive long life.

 

Solutions for Memory Challenges and Thinking Difficulties

Are you struggling with short term or long term memory? I have formulated powerful solutions to these challenges many persons with Parkinson’s symptoms confront.

The number of new and innovative therapies that improve memory and thinking has skyrocketed these past few years. Many of them you have likely never even heard about because they are so new.

There is no doubt about it. Recent research revelations are transforming how memory issues associated with Alzheimer’s can be successfully treated.

I warmly invite you to enroll in my new online course, Road to Recovery from Alzheimers. If you are confronting memory challenges, the classes posted in my new online course offer the opportunity to sharpen memory and support clear thinking.

The classes are for everyone confronting mental difficulties – not just persons with a formal diagnosis of Alzheimers.

Innovative approaches, natural therapies and dietary recommendations are all presented that nurture memory and support clear thinking. All recommendations are grounded in evidence based research findings.

Click on the link to enroll.  You have the rare opportunity to choose the course tuition you wish to pay

https://www.parkinsonsrecovery.org/offers/S6LeCHqL

Robert Rodgers PhD

X – Plus 3: New Photobiomodulation Device from Vielight

Is a problematic symptom for you involve mobility challenges? Has rock solid walking become difficult? The new Vielight X – Plus 3 device may offer the support you need to transform wobbly walking to rock solid.

The Vielight X-Plus 3 device has four components: A head module, a body module and the nasal applicator. The information below was obtained from the Vielight.com website.

Head Module

The Head Module stimulates the cerebellum. Although the cerebellum accounts for approximately 10% of the brain’s volume, it has approximately  50% of all neurons in the brain.

The cerebellum is involved in the following functions:

Maintenance of balance and posture. The cerebellum is responsible for making postural adjustments to maintain balance. It modulates commands to motor neurons to compensate for shifts in body position or changes in load upon muscles.

Coordination of voluntary movements. Most movements are composed of different muscle groups acting together in a temporally coordinated fashion. One major function of the cerebellum is to coordinate the timing and force of these different muscle groups to produce fluid limb or body movements.

Motor learning. The cerebellum is important for motor learning. The cerebellum plays a major role in adapting and fine-tuning motor programs to make accurate movements through a trial-and-error process.

Body Module

Featured in a Vielight  COVID-19 study, the body module can be used to stimulate the thymus gland to aid immune function and response. It can also be positioned over joints and certain body parts, such as the shoulder or knees, to provide anti-inflammatory relief.

Intranasal Applicator

The Intranasal Applicator is designed to improve oxygenation which  leads to increased adenosine triphosphate (ATP) levels in various tissues.

Light energy absorbed by blood through the intranasal applicator  leads to an increase in nitric oxide release.

Nitric oxide is one of the most important factors affecting microcirculation. This leads to increases in vasodilation which contributes to improved oxygen delivery to tissues.

Summary

I have no hesitation in recommending the X-Plus 3 Vielight device to be considered to address mobility challenges in particular. The company is so confident in their devices that they encourage users to use their devices for up to 6 months. If you do not receive the benefit you need, return the used device Vielight for a 80% refund.

The company also offers a 10% discount to members of the Parkinsons Recovery community. Coupon code is healing4me if you order on line. if you call to order, just claim your 10% discount by indicating you were referred by Parkinsons Recovery. The Vielight order page link is below:

X-Plus 3 (Brain Systemic)

Diabetes and Parkinson’s

The most important research discovery of the decade … There is a significant connection between diabetes and Parkinson’s

Are you tired all the time. Do you usually have little energy?

The breakdown of glucose synthesis may well be the reason. Metabolically, insulin receptors play a key role in the regulation of glucose homeostasis, Insulin signaling controls access to blood glucose in body cells.

Do you typically feel better in the morning before you have had something to eat? This is a clue that you may be susceptible to insulin resistance. Fasting over night means that is a 12 hour or more period you have not eaten anything. This is the condition needed by the body for the liver to manufacture ketones. Before eating anything in the morning. your brain is being efficiently fueled by ketones rather than glucose which is the by product of eating anything.

Epidemiological evidence and experimental data support the interaction between Parkinson’s and diabetes. Treatments for diabetes show promising neuro-protective results in PD patients for both diabetic and non-diabetic patients. Therefore, the role of anti-diabetic treatments for Parkinson’s patients offers a promising therapeutic approach.

Ask your self – why are so many persons diagnosed with neurological conditions so thin? A logical reason is that when they eat, their symptoms worsen, so they do not eat regularly

Studies that find the connection between diabetes and Parkinson’s

Mov Disord. 2022 Aug;37(8):1612-1623. The Impact of Type 2 Diabetes in Parkinson’s Disease. Dilan Athauda, James Evans, Anna Wernick, Gurvir Virdi, Minee L Choi, Michael Lawton, Nirosen Vijiaratnam, Christine Girges, Yoav Ben-Shlomo, Khalida Ismail, Huw Morris, Donald Grosset, Thomas Foltynie, Sonia Gandhi 

Abstract

Background: Type 2 diabetes (T2DM) is an established risk factor for developing Parkinson’s disease (PD), but its effect on disease progression is not well understood.

Objective: The aim of this study was to investigate the influence of T2DM on aspects of disease progression in PD.

Methods: We analyzed data from the Tracking Parkinson’s study to examine the effects of comorbid T2DM on PD progression and quality of life by comparing symptom severity scores assessing a range of motor and nonmotor symptoms.

Results: We identified 167 (8.7%) patients with PD and T2DM (PD + T2DM) and 1763 (91.3%) patients with PD without T2DM (PD). After controlling for confounders, patients with Type 2 Diabetes had more severe motor symptoms, as assessed by Movement Disorder Society Unified Parkinson’s Disease Rating Scale, Part III (25.8 [0.9] vs. 22.5 [0.3] P = 0.002), and nonmotor symptoms, as assessed by Non-Motor Symptoms Scale total (38.4 [2.5] vs. 31.8 [0.7] P < 0.001), and were significantly more likely to report loss of independence (odds ratio, 2.08; 95% confidence interval [CI]: 1.34-3.25; P = 0.001) and depression (odds ratio, 1.62; CI: 1.10-2.39; P = 0.015). Furthermore, over time, patients with T2DM had significantly faster motor symptom progression (P = 0.012), developed worse mood symptoms (P = 0.041), and were more likely to develop substantial gait impairment (hazard ratio, 1.55; CI: 1.07-2.23; P = 0.020) and mild cognitive impairment (hazard ratio, 1.7; CI: 1.24-2.51; P = 0.002) compared with the PD group. 

Conclusions: In the largest study to date, T2DM is associated with faster disease progression in Parkinson’s, highlighting an interaction between these two diseases. Because it is a potentially modifiable metabolic state, with multiple peripheral and central targets for intervention, it may represent a target for alleviating parkinsonian symptoms and slowing progression to disability and dementia. 

Mov Disord. 2021 Jun;36(6):1420-1429. Type 2 Diabetes as a Determinant of Parkinson’s Disease Risk and Progression. Harneek Chohan, Konstantin Senkevich, Radhika K Patel, Jonathan P Bestwick, Benjamin M Jacobs, Sara Bandres Ciga, Ziv Gan-Or, Alastair J Noyce 

Abstract

Background: Type 2 diabetes (T2DM) and Parkinson’s disease (PD) are prevalent diseases that affect an aging population. Previous systematic reviews and meta-analyses have explored the relationship between diabetes and the risk of PD, but the results have been conflicting. 

Objective: The objective was to investigate T2DM as a determinant of PD through a meta-analysis of observational and genetic summary data.

Methods: A systematic review and meta-analysis of observational studies was undertaken by searching 6 databases. We selected the highest-quality studies investigating the association of T2DM with PD risk and progression. We then used Mendelian randomization (MR) to investigate the causal effects of genetic liability toward T2DM on PD risk and progression, using summary data derived from genome-wide association studies.

Results: In the observational part of the study, pooled effect estimates showed that T2DM was associated with an increased risk of PD (odds ratio [OR] 1.21, 95% confidence interval [CI] 1.07-1.36), and there was some evidence that T2DM was associated with faster progression of motor symptoms (standardized mean difference [SMD] 0.55, 95% CI 0.39-0.72) and cognitive decline (SMD -0.92, 95% CI -1.50 to -0.34). Using MR, we found supportive evidence for a causal effect of diabetes on PD risk (inverse-variance weighted method [IVW] OR 1.08, 95% CI 1.02-1.14; P = 0.010) and some evidence of an effect on motor progression (IVW OR 1.10, 95% CI 1.01-1.20; P = 0.032) but not on cognitive progression.

Conclusions: Using meta-analyses of traditional observational studies and genetic data, we observed convincing evidence for an effect of T2DM on PD risk and new evidence to support a role in PD progression.

CBD Therapy for Parkinson’s

My research efforts identify recently invented or formulated products that show promise in helping to reverse symptoms of Parkinson’s disease. The CBD Therapy previewed in this post is just that – a new formulation that I think is worth seriously considering. It is called 10xPure Gold Super 1500 CBDa oil.

This formulation is a significant improvement over traditional CBD oils. It has been formulated to have 10 times the penetration and potency of other CBD products. This means you should be able to take fewer drops and spend less to celebrate symptom relief.

Once you purchase from CTFO as I have, you become an “affiliate” of the company. It is a direct sales company – not a MLM.

CTFO conducts laboratory testing on all of their samples to insure that the contents are organic and the concentrations match what is advertised. All laboratory testing is available for inspection. If a CBDa bottle is advertised to contain 450 mg of CBAa , you can be assured it does. When they advertise it is organic, you can rest assured it is.

I have no hesitation recommending this company. They generously extend a 100% money back guarantee if the product does not offer the symptom relief you seek. You only need to return the empty bottle within 60 days and your purchase price will be refunded.

There is no risk in trying this therapy out to see if it offers relief from your symptoms.

Watch the videos about 10X Pure Gold 1500 CBDa on the CTFO website by clicking on the secure link below:

https://parkinsonsrecovery.myctfo.com/product_details.html?productcode=super1500

I recommend this option because it offers the greatest concentration of CBD (450 mg) at the best price per mg. This means you will benefit from needing to take less to celebrate symptom relief.

Check out the research on CBD oil and Parkinson’s. You will be impressed with the number of studies reporting positive outcomes for symptoms of Parklnson’s disease alone.

What is CBD Oil?

CBD stands for “cannabinoid oil”. It is extracted from either the Hemp plant or Marijuana. CBD allows for the benefits of medical marijuana without the high that is associated with THC. As such, CBD in itself has no psychedelic properties and is generally considered safe for consumption. It is legal in the United States and many other countries as well.

CBD Side Effects

Studies of cannabidiol (CBD) report it is well-tolerated but may cause tiredness, diarrhea or change appetites.

Have You Already Tried CBD But Were Disappointed with the Outcome?

Know that no therapy – including CBD – will necessarily offer relief from your symptoms. Everyone has a unique body with a unique set of needs.

I have drawn the conclusion, however, that more people experience relief from their symptoms taking CBD than do not. In light of the now extensive research evidence, I have no hesitation in recommending CBD as a viable option.

There are two reasons why you might have not experienced the outcomes expected from taking CBD oil.

  • A first explanation for why some people do not experience symptom relief is that the concentration of CBD oil they took was insufficient. Research using patients diagnosed with Parkinson’s disease find that subjects who took a minimum of 300 mg showed improvement. Subjects treated with 75 mg showed no improvement.
  • A second possible explanation is that the concentration of CBD taken was less than the concentration advertised. Because there are millions of dollars to be made selling CBD which is now legal,  many overnight companies have surfaced. Some are legitimate. Others are not. A CBD product can be listed as having a 100 mg concentration of CBD (which is a low concentration) but the actual bottle contains only 25 mg or less. As a promising new health discovery, many fly by night companies have seized the opportunity to make a quick profit by selling a product that contains little of what is advertised.

Which CTFO Products Should You Try?

CTFO continues to formulate new products that all contain their patented form of cannabinoid oil. Among the many options available I recommend that you consider getting the 10X 1500 Pure Full Spectrum CBDa oil drops. Below is the description that I copied from the CTFO website. The highest dosage (450 mg) offers the best value.

“This supercharged Full Spectrum CBD oil is hydrophilic, making it easily absorbed into the body. It provides accelerated, increased absorption and potency and acts as an anti-bacterial and prebiotic. CBD has been known to support healthy blood sugar levels, promote healthy energy levels, relieve anxiety, aid in digestion, support optimal immune function and the regeneration of healthy cells, and promote a sense of serenity and overall well-being.”

Visit the page below to watch videos about CBDa and the 10xPure Gold CBD product:
https://parkinsonsrecovery.myctfo.com/product_details.html?productcode=super1500